Otsuka Pharmaceutical Companies (U.S.)

otsuka-us.com

There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

STEVANATO GROUP ANNOUNCES EXPANSION OF CORPORATE HEADQUARTERS

Stevanato Group | November 18, 2021

news image

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Group’s industrial footprint, with about 2,500 square m...

Read More

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

news image

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

EMOTET REEMERGES WITH MASSIVE CAMPAIGN TARGETING PHARMA INDUSTRY

HealthITSecurity | January 20, 2020

news image

Proofpoint is urging all organizations to take steps to shore up any vulnerabilities, after detecting a massive Emotet campaign targeting the pharmaceutical industry. The hacking group behind Emotet is known as TA542. Emotet is a modular botnet able to download and install a wide range of malware. It's also known to steal data and send malicious emails from victims. Proofpoint notes that it can easily spread across networks, leveraging infected devices to launch additional attacks. The notor...

Read More

VIEWS AND ANALYSIS

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

news image

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More
news image

PHARMACY MARKET

STEVANATO GROUP ANNOUNCES EXPANSION OF CORPORATE HEADQUARTERS

Stevanato Group | November 18, 2021

Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the expansion of its corporate headquarters with the construction of a new facility in Piombino Dese, Italy to advance operations and growth of the Company. The new 6,750 square meter facility is expected to support the optimization of Stevanato Group’s industrial footprint, with about 2,500 square m...

Read More
news image

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More
news image

EMOTET REEMERGES WITH MASSIVE CAMPAIGN TARGETING PHARMA INDUSTRY

HealthITSecurity | January 20, 2020

Proofpoint is urging all organizations to take steps to shore up any vulnerabilities, after detecting a massive Emotet campaign targeting the pharmaceutical industry. The hacking group behind Emotet is known as TA542. Emotet is a modular botnet able to download and install a wide range of malware. It's also known to steal data and send malicious emails from victims. Proofpoint notes that it can easily spread across networks, leveraging infected devices to launch additional attacks. The notor...

Read More
news image

VIEWS AND ANALYSIS

INNOVENT AND IASO BIO PRESENT UPDATED DATA OF BCMA CAR-T CELL THERAPY (EQUECABTAGENE AUTOLEUCEL) AT EHA 2022

Innovent Biologics | June 13, 2022

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and IASO Biotherapeutics a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, today jointly announced that the updated data from phase 1/2 study of Equecabtagene Autoleucel (Inno...

Read More